On the other hand, Sakurai et al., 2014 studied the combinatory effect of Luteolin and Gefinitib, a selective tyrosine kinase inhibitor that inhibits the EGFR, but also the kinase activity of cyclin G-associated kinase (GAK), on PC-3 prostate cancer cells [84]. This evidence concerns the gene GAK and prostate cancer.